Study List:

Study 1:

NCT Number: NCT04270383

Title: Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions:

Outcome Measures: The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial

Sponsor/Collaborators: Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Children’s Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University

Gender: All

Age: up to 18 Years (Child, Adult)

Phases:

Enrollment: 500

Funded Bys: Other

Study Type: Observational

Study Designs: Observational Model: Cohort|Time Perspective: Prospective

Other IDs: BCH Lung 012

Start Date: February 15, 2020

Primary Completion Date: December 31, 2020

Completion Date: December 31, 2020

First Posted: February 17, 2020

Results First Posted:

Last Update Posted: February 17, 2020

Locations: Beijing Children's Hospital,, Beijing, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04270383

Study 2:

NCT Number: NCT04259892

Title: Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection

Acronym: Cov-CONTACT

Status: Recruiting

Study Results: No Results Available

Conditions: Coronavirus

Interventions: Biological: 2019-nCoV PCR

Outcome Measures: Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact

Sponsor/Collaborators: Institut National de la Santé Et de la Recherche Médicale, France

Gender: All

Age: Child, Adult, Older Adult

Phases:

Enrollment: 300

Funded Bys: Other

Study Type: Observational

Study Designs: Observational Model: Cohort|Time Perspective: Prospective

Other IDs: C20-06|2020-A00280-39

Start Date: February 4, 2020

Primary Completion Date: October 4, 2020

Completion Date: February 4, 2021

First Posted: February 7, 2020

Results First Posted:

Last Update Posted: February 17, 2020

Locations: CIC 1425, Paris, France

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04259892

Study 3:

NCT Number: NCT04245631

Title: Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV

Acronym:

Status: Recruiting

Study Results: No Results Available

Conditions: New Coronavirus

Interventions: Diagnostic Test: Recombinase aided amplification (RAA) assay

Outcome Measures: Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%

Sponsor/Collaborators: Beijing Ditan Hospital

Gender: All

Age: 1 Year to 90 Years (Child, Adult, Older Adult)

Phases:

Enrollment: 50

Funded Bys: Other

Study Type: Observational

Study Designs: Observational Model: Cohort|Time Perspective: Prospective

Other IDs: DTXY022

Start Date: January 1, 2020

Primary Completion Date: December 31, 2020

Completion Date: December 31, 2020

First Posted: January 29, 2020

Results First Posted:

Last Update Posted: January 29, 2020

Locations: Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04245631

Study 4:

NCT Number: NCT04252664

Title: Mild/Moderate 2019-nCoV Remdesivir RCT

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions: Drug: Remdesivir|Drug: Remdesivir placebo

Outcome Measures: Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events

Sponsor/Collaborators: Capital Medical University|Chinese Academy of Medical Sciences

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 3

Enrollment: 308

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Other IDs: CAP-China remdesivir 1

Start Date: February 5, 2020

Primary Completion Date: April 10, 2020

Completion Date: April 27, 2020

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04252664

Study 5:

NCT Number: NCT04264858

Title: Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV|Immunoglobulin of Cured Patients

Interventions: Drug: Immunoglobulin of cured patients|Drug: γ-Globulin

Outcome Measures: Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality

Sponsor/Collaborators: Wuhan Union Hospital, China

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Not Applicable

Enrollment: 10

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: WuhanUH-2019 nCoV-Ig

Start Date: February 17, 2020

Primary Completion Date: April 30, 2020

Completion Date: May 31, 2020

First Posted: February 11, 2020

Results First Posted:

Last Update Posted: February 11, 2020

Locations: Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04264858

Study 6:

NCT Number: NCT04251871

Title: Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection

Acronym:

Status: Recruiting

Study Results: No Results Available

Conditions: Pneumonia Caused by Human Coronavirus (Disorder)

Interventions: Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)

Outcome Measures: Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment

Sponsor/Collaborators: Beijing 302 Hospital

Gender: All

Age: 14 Years to 80 Years (Child, Adult, Older Adult)

Phases: Not Applicable

Enrollment: 150

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: 2020001D

Start Date: January 22, 2020

Primary Completion Date: January 22, 2021

Completion Date: January 22, 2021

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations: The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04251871

Study 7:

NCT Number: NCT04261426

Title: The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions: Drug: Intravenous Immunoglobulin|Other: Standard care

Outcome Measures: Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events

Sponsor/Collaborators: Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 2|Phase 3

Enrollment: 80

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: IVIG-001

Start Date: February 10, 2020

Primary Completion Date: April 30, 2020

Completion Date: June 30, 2020

First Posted: February 7, 2020

Results First Posted:

Last Update Posted: February 7, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04261426

Study 8:

NCT Number: NCT04268537

Title: Immunoregulatory Therapy for 2019-nCoV

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019 nCoV, PD-1

Interventions: Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment

Outcome Measures: lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days

Sponsor/Collaborators: Southeast University, China

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 2

Enrollment: 120

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Other IDs: 2020YFC0841300-03

Start Date: February 10, 2020

Primary Completion Date: April 30, 2020

Completion Date: October 31, 2020

First Posted: February 13, 2020

Results First Posted:

Last Update Posted: February 13, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04268537

Study 9:

NCT Number: NCT04254874

Title: A Prospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions: Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization

Outcome Measures: Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA

Sponsor/Collaborators: Tongji Hospital

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 4

Enrollment: 100

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Other IDs: TJ20200131

Start Date: February 1, 2020

Primary Completion Date: June 1, 2020

Completion Date: July 1, 2020

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04254874

Study 10:

NCT Number: NCT04255017

Title: A Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions: Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir

Outcome Measures: Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA

Sponsor/Collaborators: Tongji Hospital

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 4

Enrollment: 400

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment

Other IDs: TJ20200128

Start Date: February 1, 2020

Primary Completion Date: June 1, 2020

Completion Date: July 1, 2020

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04255017